GlassScriptPhysician profile
Robert Morris Harpold
NPI 1134172497
$769.90
in general payments reported to CMS, 2019-2025
13 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.24 · 2021: $42.08 · 2022: $69.33 · 2023: $239 · 2024: $153 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $203.27 | 2022-2025 | |
| Amgen INC. | $132.13 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $92.99 | 2021-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $68.39 | 2020-2022 | |
| Novo Nordisk INC | $67.01 | 2023-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $43.63 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $35.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.01 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.68 | 2023 | Eliquis |
| Glaxosmithkline, LLC. | $20.27 | 2023 | Shingrix, Trelegy Ellipta |
| Biogen, INC. | $18.16 | 2021 | |
| Nevro Corp. | $18.11 | 2023 | Senza |
| Abbott Laboratories | $16.46 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Harpold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.